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Background: The prognostic significance of transient hypotension during hospitalization for acute decompensated heart failure (ADHF) is 
uncertain. We evaluated factors associated with hypotension and its relationship with 30-day (30d) outcomes in the ASCEND-HF trial (which 
randomized patients without baseline hypotension to nesiritide or placebo).
methods: Hypotension episodes in ASCEND-HF were defined as symptomatic or asymptomatic per investigator. Stepwise logistic regression was 
used to identify baseline factors related to hypotension, and a Cox proportional hazards model was used to examine the relationship between 
hypotension and 30d outcomes, including the interaction with nesiritide.
results: Of 7,141 randomized patients, 1,555 (21.8%) had hypotension during hospitalization, with 27% symptomatic (median SBP 80mmHg, 
IQR 70-87), 73% asymptomatic (median SBP 83mmHg, IQR 79-88), and at median time 17.2h (IQR 5.2-30.8h). Table shows factors associated 
with hypotension. Nesiritide was used in 62.7% of patients experiencing hypotension and 46.4% of patients without hypotension. Hypotension was 
independently associated with 30d mortality (HR 2.16, p<0.001), but there was no interaction between nesiritide and hypotension on 30d mortality 
(p=0.26).
conclusion: Hypotension is common during hospitalization for ADHF and is a major prognostic factor for 30d mortality independent of nesiritide 
therapy. Severity of heart failure and other factors contribute to risk of hypotension. 
Table: Results of a multivariate associative model for hypotension in ADHF
Variable Odds Ratio Confidence Interval p-value
Age (per year age >61 years) 1.01 1.00-1.02 0.003
Race
Black 0.73 0.60-0.88 0.001
Asian 0.57 0.35-0.92 0.021
Other 1.15 0.83-1.60 0.40
Measurements
Temperature (for each degree >36.4C) 1.40 1.13-1.74 0.002
SBP <= 127 (per each 1 mmHg increase) 0.96 0.95-0.97 <0.001
SBP >127 (per each 1 mmHg increase) 0.99 0.98-0.99 <0.001
Heart Rate <= 75 beats/minute 1.02 1.01-1.03 0.001
Baseline Sodium <=146 0.97 0.96-0.99 <0.001
Baseline Sodium >146 0.76 0.57-1.02 0.065
Characteristics
Baseline orthopnea 1.32 1.14-1.54 0.001
Baseline S3 gallop 1.24 1.08-1.42 0.003
Region (compared to North America)
Asia Pacific 0.98 0.61-1.58 0.93
Central Europe 0.45 0.36-0.56 <0.001
Latin America 0.69 0.54-0.88 0.003
Western Europe 0.99 0.78-1.26 0.92
Medications
Planned nesiritide therapy 2.08 1.84-2.35 <0.001
